Navidea Biopharmaceuticals (NAVB)
(Delayed Data from OTC)
$0.00 USD
0.00 (0.00%)
Updated Aug 27, 2024 02:02 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Navidea Biopharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 2 | 4 | 3 | 1 |
Receivables | NA | 0 | 0 | 3 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 1 | 1 | 1 |
Total Current Assets | NA | 3 | 5 | 7 | 3 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 1 | 1 | 1 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 1 |
Total Assets | NA | 4 | 7 | 8 | 4 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | 1 | 0 | 1 | 0 |
Accounts Payable | NA | 2 | 1 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 6 | 3 | 3 | 2 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 1 | 0 | 0 | 0 |
Total Current Liabilities | NA | 10 | 5 | 5 | 4 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 1 | 1 | 1 | 1 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 2 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 13 | 6 | 6 | 5 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | -10 | 0 |
Common Stock (Par) | NA | 0 | 0 | -5 | 0 |
Capital Surplus | NA | 379 | 370 | 375 | 346 |
Retained Earnings | NA | -388 | -371 | -359 | -348 |
Other Equity | NA | 0 | 1 | 1 | 1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -8 | 1 | 2 | -1 |
Total Liabilities & Shareholder's Equity | NA | 4 | 7 | 8 | 4 |
Total Common Equity | 0 | -8 | 1 | 12 | -1 |
Shares Outstanding | 100.00 | 32.10 | 30.10 | 26.60 | 18.00 |
Book Value Per Share | 0.00 | -0.25 | 0.02 | 0.46 | -0.05 |
Fiscal Year End for Navidea Biopharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | -99,999 | 4 | 6 |
Receivables | NA | NA | NA | 0 | 0 |
Notes Receivable | NA | NA | NA | 0 | 0 |
Inventories | NA | NA | NA | 0 | 0 |
Other Current Assets | NA | NA | NA | 0 | 0 |
Total Current Assets | NA | NA | NA | 5 | 7 |
Net Property & Equipment | NA | NA | NA | 0 | 0 |
Investments & Advances | NA | NA | NA | 0 | 0 |
Other Non-Current Assets | NA | NA | NA | 0 | 0 |
Deferred Charges | NA | NA | NA | 0 | 0 |
Intangibles | NA | NA | NA | 1 | 1 |
Deposits & Other Assets | NA | NA | NA | 0 | 0 |
Total Assets | NA | NA | NA | 6 | 8 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | 1 | 1 |
Accounts Payable | NA | NA | NA | 2 | 2 |
Current Portion Long-Term Debt | NA | NA | NA | 0 | 0 |
Current Portion Capital Leases | NA | NA | NA | 0 | 0 |
Accrued Expenses | NA | NA | NA | 4 | 4 |
Income Taxes Payable | NA | NA | NA | 0 | 0 |
Other Current Liabilities | NA | NA | NA | 1 | 1 |
Total Current Liabilities | NA | NA | NA | 8 | 8 |
Mortgages | NA | NA | NA | 0 | 0 |
Deferred Taxes/Income | NA | NA | NA | 1 | 1 |
Convertible Debt | NA | NA | NA | 0 | 0 |
Long-Term Debt | NA | NA | NA | 0 | 0 |
Non-Current Capital Leases | NA | NA | NA | 0 | 0 |
Other Non-Current Liabilities | NA | NA | 0 | 0 | |
Minority Interest (Liabilities) | NA | NA | NA | 0 | 0 |
Total Liabilities | NA | NA | NA | 9 | 9 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | 0 | 0 |
Common Stock (Par) | NA | NA | NA | 0 | 0 |
Capital Surplus | NA | NA | NA | 382 | 382 |
Retained Earnings | NA | NA | NA | -386 | -384 |
Other Equity | NA | NA | NA | 0 | 0 |
Treasury Stock | NA | NA | NA | 0 | 0 |
Total Shareholder's Equity | NA | NA | NA | -3 | -1 |
Total Liabilities & Shareholder's Equity | NA | NA | NA | 6 | 8 |
Total Common Equity | 0 | 0 | 0 | -3 | -1 |
Shares Outstanding | 100.00 | 100.00 | 100.00 | 100.00 | 96.10 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | -0.03 | -0.01 |